Martin and Harris Laboratories Limited
52W HIGH
Rs 969
52W LOW
Rs 867
1Y RETURN
+5.3%
About the Company
Martin & Harris Laboratories Limited is a pharmaceutical company engaged in contract manufacturing and branded formulations, historically associated with the Apeejay Stya group. The company’s portfolio spans therapeutic segments including anti-infectives, pain management, respiratory and gastro-intestinal. Facilities and quality systems align with Indian regulatory standards, and the company collaborates with distribution partners for domestic reach. Corporate materials trace legacy brands and manufacturing capabilities supporting scale, compliance and patient accessibility across selected markets.
Quick Facts
As of 7 Jul 2026
Quantity
Minimum investment Rs 1,00,000 (110 shares).
Settled in T+1 days. KYC verified dealers.
Get Martin and Harris Laboratories Limited's live price
Share a few details and our desk sends you the latest price, availability and how to invest.
Trusted by 5,000+ investors · your details are never shared.
FUNDAMENTALS
Key Indicators
A snapshot of Martin and Harris Laboratories Limited's valuation multiples and capital efficiency at a glance.
CURRENT SHARE PRICE
Rs 912.9
FACE VALUE / SHARE
Rs 10
BOOK VALUE / SHARE
Rs 1,794.25
PRICE TO EARNING (PE)
5.39
PRICE / BOOK
0.50
MARKET CAP
364.8 Cr
DEBT TO EQUITY
0.02
RETURN ON EQUITY
9.39%
52 WEEK HIGH
Rs 969
52 WEEK LOW
Rs 867
FINANCIALS
Fundamentals & Financial Statements
Price / Share
₹895
P/E Ratio
5.39
P/B Ratio
0.50
Debt to Equity
0.02
Book Value
₹1,794.25
Face Value
₹10
| Particulars | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 186 | 205 | 146 | 107.4 |
| Cost of Material Consumed | 50 | 47 | 41 | 44 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Gross Margins | 73.12% | 77.07% | 71.92% | 59.03% |
| Employee Benefit Expenses | 19 | 25 | 24 | 17 |
| Other Expenses | 47 | 61 | 55 | 38 |
| EBITDA | 70 | 72 | 26 | 8.4 |
| OPM | 37.63% | 35.12% | 17.81% | 7.82% |
| Other Income | 26 | 24 | 34 | 80.5 |
| Finance Cost | 0.15 | 0 | 0.6 | 1.1 |
| Depreciation & Amortisation | 3 | 4 | 5 | 4.8 |
| EBIT | 67 | 68 | 21 | 3.6 |
| EBIT Margins | 36.02% | 33.17% | 14.38% | 3.35% |
| Profit Before Tax | 93 | 92 | 55 | 83 |
| PBT Margins | 50% | 44.88% | 37.67% | 77.28% |
| Tax | 23 | 24 | 15 | 16.6 |
| Profit After Tax | 70 | 68 | 40 | 66.4 |
| Net Profit Margin | 37.63% | 33.17% | 27.4% | 61.82% |
| EPS | ₹175.44 | ₹170.43 | ₹100.25 | ₹166.42 |
PROCESS
How to Buy Martin and Harris Laboratories Limited
Enquire
Share your requirement and preferred quantity with our desk.
Get a quote
Receive the latest indicative price, lot size and availability.
Complete KYC
Quick paperwork with a KYC-verified counterparty.
Receive shares
Shares credited to your demat, typically within T+1 days.
OWNERSHIP
Shareholding Pattern
Indicative ownership structure. Exact filed breakup confirmed at dealing.
CORPORATE CALENDAR
Events & Announcements
Typical annual calendar. Exact dates updated as the company announces them.
LEADERSHIP
Management Team
Standard governance structure. Named directors added as verified. Tap any role to see what they do and why it matters for investors.
REPORTS
Download Financial Results
Martin and Harris Laboratories Limited Financial Report
Fundamentals, financial statements and key ratios in one PDF
Need the official filed reports?
Get audited annual & quarterly filings (MCA / RTA) for Martin and Harris Laboratories Limited straight from our desk.
QUESTIONS
Frequently Asked Questions
NEWS & INSIGHTS
Latest on Martin and Harris Laboratories Limited & its sector
CORPORATE
Company Details
ISIN
INE03VV01015
CIN
U24239HR1993PLC033630
PAN
AABCM0832A
REGISTRAR (RTA)
RCMC Share Registry Pvt. Ltd
DEPOSITORY
NSDL Only
INCORPORATED
Jul 1993
OUTSTANDING SHARES
39,96,040
REGISTERED OFFICE
NH-8, DELHI JAIPUR HIGHWAY, VILLAGE, PACHGAON (FAZALWAS), DISTT. GURGAON, HARYANA HR IN 000000, India
SECTOR
Health Care
INDUSTRY
Pharmaceuticals
READY TO INVEST?
Enquire with Neoma Capital
Talk to a CA advisor about Martin and Harris Laboratories Limited. Get pricing, availability, and transfer process guidance.
Disclaimer: Prices shown are indicative and for reference purposes only. Unlisted shares carry higher risk than listed equities. Past performance is not indicative of future results. Financial statements, where shown, are compiled from company filings (MCA / RTA) and may be restated in subsequent filings. Neoma Capital does not provide investment advice. Please consult a qualified financial advisor. Transactions subject to KYC verification and SEBI regulations.